Regulatory Focus™ > News Articles > Brazil's Anvisa Pushes Expedited Approvals for Generics, Biologics

Brazil's Anvisa Pushes Expedited Approvals for Generics, Biologics

Posted 04 June 2014 | By Louise Zornoza

Brazil's Anvisa Pushes Expedited Approvals for Generics, Biologics

Brazilian regulator Anvisa has launched a simplified procedure (RDC No. 31) for the registration, post-registration and renewal of registration of generic, similar, herbal, biologic, “dynamized” and “specific” drugs. 

So-called "dynamized" drugs in Brazil are preparations from substances that are subjected to successive dilutions, that are administered as homeopathic, anthroposophic or homotoxicological therapy.  Specific drugs are products that do not fit into other categories and cannot be tested for bioequivalence against a reference drug.

According to Anvisa, the new procedure will reduce by approximately 30% the time that it takes for it to review and approve a marketing approval application. Companies wishing to apply for registration of medicines in accordance with the new regulation may do so exclusively via electronic application, as of 4 June 2014. 

 

This content is provided by RegLink Associates. Read all of their Breaking News alerts on their website.


Categories: Regulatory News

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe